IL165051A0 - New compounds useful for the treatment of obesity,type II diabetes and cns disorders - Google Patents

New compounds useful for the treatment of obesity,type II diabetes and cns disorders

Info

Publication number
IL165051A0
IL165051A0 IL16505104A IL16505104A IL165051A0 IL 165051 A0 IL165051 A0 IL 165051A0 IL 16505104 A IL16505104 A IL 16505104A IL 16505104 A IL16505104 A IL 16505104A IL 165051 A0 IL165051 A0 IL 165051A0
Authority
IL
Israel
Prior art keywords
obesity
diabetes
treatment
type
compounds useful
Prior art date
Application number
IL16505104A
Original Assignee
Biovitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0201925A external-priority patent/SE0201925D0/en
Priority claimed from SE0202181A external-priority patent/SE0202181D0/en
Priority claimed from SE0202908A external-priority patent/SE0202908D0/en
Priority claimed from SE0300357A external-priority patent/SE0300357D0/en
Application filed by Biovitrum Ab filed Critical Biovitrum Ab
Publication of IL165051A0 publication Critical patent/IL165051A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL16505104A 2002-06-20 2004-11-04 New compounds useful for the treatment of obesity,type II diabetes and cns disorders IL165051A0 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
SE0201925A SE0201925D0 (en) 2002-06-20 2002-06-20 New compounds
SE0202181A SE0202181D0 (en) 2002-07-11 2002-07-11 New compounds
US40612002P 2002-08-26 2002-08-26
SE0202908A SE0202908D0 (en) 2002-10-01 2002-10-01 New compounds
US43401002P 2002-12-17 2002-12-17
SE0300357A SE0300357D0 (en) 2003-02-10 2003-02-10 New compounds
US46470103P 2003-04-23 2003-04-23
PCT/SE2003/001061 WO2004000828A1 (en) 2002-06-20 2003-06-19 New compounds useful for the treatment of obesity, type ii diabetes and cns disorders

Publications (1)

Publication Number Publication Date
IL165051A0 true IL165051A0 (en) 2005-12-18

Family

ID=30004107

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16505104A IL165051A0 (en) 2002-06-20 2004-11-04 New compounds useful for the treatment of obesity,type II diabetes and cns disorders

Country Status (13)

Country Link
EP (1) EP1513828A1 (en)
CN (1) CN1662521A (en)
AU (1) AU2003243091A1 (en)
BR (1) BR0311952A (en)
CA (1) CA2486989A1 (en)
EA (2) EA011581B1 (en)
IL (1) IL165051A0 (en)
MX (1) MXPA04012914A (en)
NO (1) NO20050294L (en)
NZ (3) NZ536600A (en)
RS (1) RS111204A (en)
SG (1) SG156524A1 (en)
WO (1) WO2004000828A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2307919T3 (en) 2002-03-27 2008-12-01 Glaxo Group Limited DERIVATIVES OF QUINOLINA AND ITS USE AS LIGANDS OF 5-HT6.
SE0301446D0 (en) 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
PT1558582E (en) 2003-07-22 2006-05-31 Arena Pharm Inc DIARIL- AND ARIL-HETEROARIL-UREA DERIVATIVES AS SEROTONIN 5-HT2A RECEPTOR MODULES USEFUL FOR PROPHYLAXIS AND TREATMENT OF RELEVANT DISORDERS
SE0302760D0 (en) * 2003-10-20 2003-10-20 Biovitrum Ab New compounds
BRPI0417833A (en) * 2003-12-19 2007-04-17 Biovitrum Ab benzofuran derivatives which may be used for the prophylaxis or treatment of 5-ht6 receptor-related disorders
SE0303480D0 (en) 2003-12-19 2003-12-19 Biovitrum Ab Benzofuranes
GB0407025D0 (en) * 2004-03-29 2004-04-28 Glaxo Group Ltd Novel compounds
TWI380816B (en) * 2004-04-13 2013-01-01 Synta Pharmaceuticals Corp Disalt inhibitors of il-12 production
WO2006062481A1 (en) * 2004-12-09 2006-06-15 Biovitrum Ab New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders .
AR054044A1 (en) * 2005-05-23 2007-05-30 Astrazeneca Ab CHROMAN AND TETRAHYDRONAFTALENE DERIVATIVES AS RECEPTOR MODULATORS 5 - HT6; INTERMEDIARIES IN THEIR PREPARATION; PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR EMPELO IN THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF CNS AND OBESITY DISEASES.
US7582767B2 (en) 2005-06-17 2009-09-01 Biovitrum Ab (Publ.) Substituted sulphonamide compound and uses thereof
EP1907384A2 (en) * 2005-06-30 2008-04-09 Prosidion Limited Gpcr agonists
KR20140033237A (en) 2005-10-07 2014-03-17 엑셀리시스, 인코포레이티드 Phosphatidylinositol 3-kinase inhibitors and methods of their use
WO2007051735A1 (en) 2005-11-03 2007-05-10 F. Hoffmann-La Roche Ag Arylsulfonylchromans as 5-ht6 inhibitors indolylmaleimide derivatives as protein kinase inhibitors
UY30048A1 (en) 2005-12-23 2007-07-31 Astrazeneca Ab SUBSTITUTED DERIVATIVES OF THE N, 2- (1H-BENZIMIDAZOL-1-IL) ACETAMIDE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION PROCESSES AND APPLICATIONS
CA2654822A1 (en) 2006-06-20 2007-12-27 F. Hoffmann-La Roche Ag Arylsulfonyl naphthalene derivatives and uses thereof
CN101472884A (en) 2006-06-20 2009-07-01 弗·哈夫曼-拉罗切有限公司 1 2 3 4-tetralin and indane derivatives and uses thereof
JP2009541248A (en) 2006-06-20 2009-11-26 エフ．ホフマン−ラ ロシュ アーゲー Arylsulfonamidyltetralin derivatives and their use
TWI433839B (en) 2006-08-11 2014-04-11 Neomed Inst New benzimidazole derivatives 290
EP2254564A1 (en) 2007-12-12 2010-12-01 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US7888662B2 (en) 2008-06-20 2011-02-15 Varian Semiconductor Equipment Associates, Inc. Ion source cleaning method and apparatus
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
WO2012154194A1 (en) * 2011-05-09 2012-11-15 Forma Tm, Llc Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (nampt)
US9663498B2 (en) 2013-12-20 2017-05-30 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic compounds and their application in pharmaceuticals
RU2017145976A (en) 2015-06-12 2019-07-15 Аксовант Сайенсиз Гмбх Diaryl- and arylheteroarylurea derivatives applicable for the prevention and treatment of behavioral disturbances during the REM phase of sleep
KR20180064373A (en) 2015-07-15 2018-06-14 엑소반트 사이언시즈 게엠베하 Diaryl and aryl heteroaryl urea derivatives as modulators of 5-HT2A serotonin receptors useful for the prevention and treatment of hallucinations associated with neurodegenerative diseases
WO2017147328A1 (en) 2016-02-23 2017-08-31 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB947606A (en) * 1961-04-10 1964-01-22 Ici Ltd N-substituted piperazines
US4808595A (en) * 1986-12-24 1989-02-28 Merck & Co., Inc. Furopyridine sulfonamides and their opthalmological compositions
WO1994021619A1 (en) * 1993-03-16 1994-09-29 Pfizer Inc. Naphthalene derivatives
US5597826A (en) * 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
DZ2376A1 (en) * 1996-12-19 2002-12-28 Smithkline Beecham Plc New sulfonamide derivatives process for their preparation and pharmaceutical compositions containing them.
GB9818916D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
GB9904995D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Substituted aza-oxindole derivatives
GB9926302D0 (en) * 1999-11-05 2000-01-12 Smithkline Beecham Plc Novel compounds
WO2001032660A1 (en) * 1999-11-05 2001-05-10 Nps Allelix Corp. Compounds having 5-ht6 receptor antagonist activity
WO2001085722A1 (en) * 2000-05-05 2001-11-15 Cor Therapeutics, Inc. Heterobicyclic sulfonamides and their use as platelet adp receptor inhibitors
MXPA02010763A (en) * 2000-06-14 2003-03-10 Warner Lambert Co 6,5-fused bicyclic heterocycles.
MXPA03003397A (en) * 2000-10-20 2004-06-30 Biovitrum Ab 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy.
PL366619A1 (en) * 2001-05-11 2005-02-07 Biovitrum Ab Novel, arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders
EP1401813B1 (en) * 2001-06-07 2007-02-07 F. Hoffman-la Roche AG New indole derivatives with 5-ht6 receptor affinity
EA008476B1 (en) * 2001-06-11 2007-06-29 Биовитрум Аб Substituted sulfonamide compounds, process for their use as medicaments for the treatment of cns disorders, obesity and type ii diabetes

Also Published As

Publication number Publication date
AU2003243091A1 (en) 2004-01-06
BR0311952A (en) 2005-04-19
EA200500054A1 (en) 2005-06-30
EA200600975A1 (en) 2006-10-27
CA2486989A1 (en) 2003-12-31
NZ536600A (en) 2007-08-31
WO2004000828A1 (en) 2003-12-31
NZ552283A (en) 2008-07-31
MXPA04012914A (en) 2005-03-31
NZ552282A (en) 2008-07-31
EA011581B1 (en) 2009-04-28
CN1662521A (en) 2005-08-31
RS111204A (en) 2006-12-15
EA008835B1 (en) 2007-08-31
SG156524A1 (en) 2009-11-26
NO20050294L (en) 2005-02-04
EP1513828A1 (en) 2005-03-16

Similar Documents

Publication Publication Date Title
IL165051A0 (en) New compounds useful for the treatment of obesity,type II diabetes and cns disorders
HK1066790A1 (en) Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes
HK1068335A1 (en) Novel arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders
AU2003281978A1 (en) 2,5-diketopiperazines for the treatment of obesity
AU2003299791A1 (en) Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
IL165257A0 (en) 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obestity anddyslipidemia
SI1474416T1 (en) Dihydrobenzodiazepin-2-one-derivatives for the treatment of neurological disorders
AU2003207717B9 (en) 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
HK1087103A1 (en) Anilinopyrazole derivatives useful for the treatment of diabetes
MXPA03007960A (en) Compounds and methods for the treatment of urogenital disorders.
EP1625207A4 (en) Compounds for treatment of inflammation, diabetes and related disorders
IL209842A0 (en) Compounds for the treatment of metabolic disorders
AP2005003274A0 (en) Thiazole compounds for the treatment of neurodegenerative disorders
EP1534074A4 (en) Combination therapy for the treatment of obesity
AU2002258428A1 (en) Methods for the treatment of metabolic disorders, including obesity and diabetes
AU2003279442A8 (en) 2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes
AU2003286728A8 (en) Compounds for the treatment of metabolic disorders
AU2003282156A8 (en) Use of prebiotics, preferably glucooligosaccharide, for the prevention of the onset of type ii diabetes
IL165242A0 (en) Treatment for diabetes
HRP20041160A2 (en) Novel combination for the treatment of airway disorders
AU2002354698A1 (en) Use of xaa-pro peptidases for the treatment of substance p-related disorders
ZA200409030B (en) New compounds useful for the treatment of obesity,type ii diabetes and CNS disorders.
AU2003239967A1 (en) Compound for the treatment of cns disorders
AU2003243214A1 (en) Salts of bis-arylsulfones for the treatment of cns disorders
HRP20041159A2 (en) Combination for the treatment of airway disorders